HLS Stock Overview
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.25 |
| 52 Week High | AU$3.26 |
| 52 Week Low | AU$1.09 |
| Beta | 0.65 |
| 1 Month Change | -0.80% |
| 3 Month Change | -12.32% |
| 1 Year Change | -59.71% |
| 3 Year Change | -70.43% |
| 5 Year Change | -60.22% |
| Change since IPO | -73.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLS | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 5.5% | -2.9% | -3.0% |
| 1Y | -59.7% | -24.0% | 3.9% |
Return vs Industry: HLS underperformed the Australian Healthcare industry which returned -24% over the past year.
Return vs Market: HLS underperformed the Australian Market which returned 3.9% over the past year.
Price Volatility
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: HLS has not had significant price volatility in the past 3 months.
Volatility Over Time: HLS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 10,500 | Paul Anderson | www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| HLS fundamental statistics | |
|---|---|
| Market cap | AU$907.62m |
| Earnings (TTM) | -AU$984.10m |
| Revenue (TTM) | AU$1.69b |
0.5x
P/S Ratio-0.9x
P/E RatioIs HLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLS income statement (TTM) | |
|---|---|
| Revenue | AU$1.69b |
| Cost of Revenue | AU$1.16b |
| Gross Profit | AU$532.00m |
| Other Expenses | AU$1.52b |
| Earnings | -AU$984.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 31.45% |
| Net Profit Margin | -58.17% |
| Debt/Equity Ratio | 39.3% |
How did HLS perform over the long term?
See historical performance and comparison